Ionis Pharmaceuticals Inc [IONS] stock is trading at $28.38, down -1.05%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The IONS shares have gain 11.25% over the last week, with a monthly amount drifted -17.26%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ionis Pharmaceuticals Inc [NASDAQ: IONS] stock has seen the most recent analyst activity on April 07, 2025, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $45. Previously, Redburn Atlantic started tracking the stock with Neutral rating on March 31, 2025, and set its price target to $39. On August 02, 2024, downgrade downgraded it’s rating to Market Perform and revised its price target to $60 on the stock. Leerink Partners upgraded its rating to a Outperform and increased its price target to $62 on July 24, 2024. Bernstein upgraded its rating to Mkt Perform for this stock on June 14, 2024, but kept the price target unchanged to $44. In a note dated April 10, 2024, Wolfe Research upgraded an Outperform rating on this stock but restated the target price of $58.
Ionis Pharmaceuticals Inc [IONS] stock has fluctuated between $23.95 and $52.34 over the past year. Currently, Wall Street analysts expect the stock to reach $51.68 within the next 12 months. Ionis Pharmaceuticals Inc [NASDAQ: IONS] shares were valued at $28.38 at the most recent close of the market. An investor can expect a potential return of 82.1% based on the average IONS price forecast.
Analyzing the IONS fundamentals
Ionis Pharmaceuticals Inc [NASDAQ:IONS] reported sales of 705.56M for the trailing twelve months, which represents a drop of -30.15%. Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -0.67%, Pretax Profit Margin comes in at -0.65%, and Net Profit Margin reading is -0.64%. To continue investigating profitability, this company’s Return on Assets is posted at -0.15, Equity is -1.0 and Total Capital is -0.18. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of2.41.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 28.04 points at the first support level, and at 27.69 for the second support level. However, for the 1st resistance point, the stock is sitting at 28.85, and for the 2nd resistance point, it is at 29.31.
Ratios To Look Out For
For context, Ionis Pharmaceuticals Inc’s Current Ratio is 8.47. Further, the Quick Ratio stands at 8.43, while the Cash Ratio is 0.78. Considering the valuation of this stock, the price to sales ratio is 6.39, the price to book ratio is 7.62.
Transactions by insiders
Recent insider trading involved Monia Brett P, Chief Executive Officer, that happened on Mar 11 ’25 when 140.0 shares were sold. Officer, Monia Brett P completed a deal on Mar 11 ’25 to buy 140.0 shares. Meanwhile, EVP CLO & General Counsel O’NEIL PATRICK R. sold 1207.0 shares on Feb 20 ’25.
